Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Running

IMPACT IMPlementation of Affordable gene Correction Therapies

Coordinator
Universitair Medisch Centrum Utrecht, Netherlands
Runs
1 January 2025 to 30 June 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101189464

What the project is doing

In the project's own words, from its summary on CORDIS.

Rare genetic diseases affect over 30 million people in Europe. Although individually rare and very diverse, they are all caused by genetic mutations. Recent progress in genetic technologies now holds the promise to correct the root cause of these diseases. However, it remains difficult to develop these innovative technologies into affordable therapies for these diseases that only affect few patients, limiting commercial interest.

IMPACT aims to overcome the translational gap between scientific gene editing and in human gene correction therapies that will be affordable and readily available for patients with rare genetic diseases. To overcome this gap, we will use a multifaceted approach to set up the infrastructure for a gene correction therapy for Methylmalonic Acidemia (MMA) by elucidating and addressing the essential (1) regulatory, (2) manufacturing, and (3) financial requirements.

This approach involves preclinical testing of the therapy in a perfused ex vivo human liver, clarifying the intellectual property strategy, and involving experts, stakeholders, and end users to define the regulatory, manufacturing, and financial strategies required for academic development and clinical implementation. As such, IMPACT aims to valorise the innovative gene correction strategy developed with the ERC Starting Grant to deliver prime editing tools as mRNA encapsulated in lipid nanoparticles to correct the disease-causing mutation in the liver of patients with MMA.With IMPACT, we do not only aim to develop gene correction therapies in our academic hospital for MMA.

Through our efforts in generating the infrastructure for a therapeutic platform approach with only slight adaptations to target different mutations, we ultimately aim to develop therapies for the many patients with different genetic diseases.

Topics

Who is involved

OrganisationCityCountryRole
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI